Curevac N.V. (CVAC) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CureVac N.V., a leader in mRNA technology, has partnered with MD Anderson Cancer Center to co-develop mRNA-based cancer vaccines targeting high-need hematological and solid tumor indications. Leveraging CureVac’s expertise in mRNA vaccine design and manufacturing, alongside MD Anderson’s prowess in translational and clinical research, the collaboration is set to lead Phase 1/2 studies with the goal of crafting off-the-shelf therapeutic solutions for cancer patients. CureVac holds exclusive rights to any late-stage development and commercialization of the vaccine candidates emerging from this partnership.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.